USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs

Lung Cancer

Volumn 107, Issue , 2017, Pages 41-49

  Malapelle, Umberto ^a   Morra, Francesco ^b   Ilardi, Gennaro ^a   Visconti, Roberta ^b   Merolla, Francesco ^a   Cerrato, Aniello ^b   Napolitano, Virginia ^b   Monaco, Roberto ^c   Guggino, Gianluca ^c   Monaco, Guglielmo ^c   Staibano, Stefania ^a   Troncone, Giancarlo ^a   Celetti, Angela ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

^c CARDARELLI HOSPITAL   (Italy)

Author keywords

CCDC6; L NET; NGS; P5091; PARP Inhibitors; USP7

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; CASPASE 8; CISPLATIN; CYCLINE; CYCLOHEXIMIDE; CYTOCHROME C; DEUBIQUITINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; P 5091; PROTEIN KINASE LKB1; PROTEIN P53; SCATTER FACTOR RECEPTOR; TUBULIN; UNCLASSIFIED DRUG; USP7 INHIBITOR; USP7 PROTEIN; CCDC6 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; P5091; PROTEIN SERINE THREONINE KINASE; STK11 PROTEIN, HUMAN; THIOPHENE DERIVATIVE; TP53 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN CARBOXYL TERMINAL HYDROLASE 7; UBIQUITIN THIOLESTERASE; USP7 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CELL; CCDC6 GENE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG SENSITIZATION; FEMALE; GENE PRODUCT; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG NEUROENDOCRINE CANCER CELL; MALE; MUTATION; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE; ANTAGONISTS AND INHIBITORS; CARCINOMA; DRUG EFFECTS; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG TUMOR; METABOLISM; MIDDLE AGED; NEUROENDOCRINE TUMOR; PATHOLOGY; PREDICTIVE VALUE; PROTEIN PROCESSING; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NEUROENDOCRINE; CISPLATIN; CYTOSKELETAL PROTEINS; DOWN-REGULATION; FEMALE; GENES, P53; GENES, TUMOR SUPPRESSOR; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEUROENDOCRINE TUMORS; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; THIOPHENES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; UBIQUITIN-SPECIFIC PEPTIDASE 7;

EID: 84977642485     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.06.015     Document Type: Article

References (33)

1. [1] Pelosi, G., Fabbri, A., Cossa, M., Sonzogni, A., Valeri, B., Righi, L., Papotti, M., What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?. Semin. Diagn. Pathol. 32:6 (2015), 469–479, 10.1053/j.semdp.
2. [2] Schnabel, P.A., Junker, K., Pulmonary neuroendocrine tumors in the new WHO 2015 classification: start of breaking new grounds?. Pathologe 36:3 (2015), 283–292, 10.1007/s00292-015-0030-2.
3. [3] Edge, S.B., Byrd, D.R., Compton, C.C., Fritz, A.G., Greene, F.L., Trotti, A., (eds.) AJCC Cancer Staging Manual, 7th edn., 2010, Springer, New York, 253–270 ISBN 978-0-387-88440-0.
4. [4] Rindi, G., Klersy, C., Inzani, F., Fellegara, G., Ampollini, L., Ardizzoni, A., Campanini, N., Carbognani, P., De Pas, T.M., Galetta, D., Granone, P.L., Righi, L., Rusca, M., Spaggiari, L., Tiseo, M., Viale, G., Volante, M., Papotti, M., Pelosi, G., Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr. Relat. Cancer 21:1 (2013), 1–16, 10.1530/ERC-13-0246.
5. [5] Curtin, N.J., DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer(12), 2012, 801–817, 10.1038/nrc3399.
6. [6] Fernandez-Cuesta, L., Peifer, M., Lu, X., et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat. Commun., 5, 2014, 3518, 10.1038/ncomms4518.
7. [7] George, J., Lim, J.S., Jang, S.J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X., Fernández-Cuesta, L., Bosco, G., Müller, C., Dahmen, I., Jahchan, N.S., Park, K.S., Yang, D., Karnezis, A.N., Vaka, D., Torres, A., Wang, M.S., Korbel, J.O., Menon, R., Chun, S.M., Kim, D., Wilkerson, M., Hayes, N., Engelmann, D., Pützer, B., Bos, M., Michels, S., Vlasic, I., Seidel, D., Pinther, B., Schaub, P., Becker, C., Altmüller, J., Yokota, J., Kohno, T., Iwakawa, R., Tsuta, K., Noguchi, M., Muley, T., Hoffmann, H., Schnabel, P.A., Petersen, I., Chen, Y., Soltermann, A., Tischler, V., Choi, C.M., Kim, Y.H., Massion, P.P., Zou, Y., Jovanovic, D., Kontic, M., Wright, G.M., Russell, P.A., Solomon, B., Koch, I., Lindner, M., Muscarella, L.A., la Torre, A., Field, J.K., Jakopovic, M., Knezevic, J., Castaños-Vélez, E., Roz, L., Pastorino, U., Brustugun, O.T., Lund-Iversen, M., Thunnissen, E., Köhler, J., Schuler, M., Botling, J., Sandelin, M., Sanchez-Cespedes, M., Salvesen, H.B., Achter, V., Lang, U., Bogus, M., Schneider, P.M., Zander, T., Ansén, S., Hallek, M., Wolf, J., Vingron, M., Yatabe, Y., Travis, W.D., Nürnberg, P., Reinhardt, C., Perner, S., Heukamp, L., Büttner, R., Haas, S.A., Brambilla, E., Peifer, M., Sage, J., Thomas, R.K., Comprehensive genomic profiles of small cell lung cancer. Nature 524:7563 (2015), 47–53, 10.1038/nature14664.
8. [8] Swarts, D.R., Ramaekers, F.C., Speel, E.J., Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochim. Biophys. Acta 1826 (2012), 255–271, 10.1016/j.bbcan.2012.05.001.
9. [9] Debelenko, L.V., Brambilla, E., Agarwal, S.K., Swalwell, J.I., Kester, M.B., Lubensky, I.A., Zhuang, Z., Guru, S.C., Manickam, P., Olufemi, S.E., Chandrasekharappa, S.C., Crabtree, J.S., Kim, Y.S., Heppner, C., Burns, A.L., Spiegel, A.M., Marx, S.J., Liotta, L.A., Collins, F.S., Travis, W.D., Emmert-Buck MR identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum. Mol. Genet. 6:13 (1997), 2285–2290.
10. [10] Peifer, M., Fernández-Cuesta, L., Sos, M.L., George, J., Seidel, D., Kasper, L.H., Plenker, D., Leenders, F., Sun, R., Zander, T., Menon, R., Koker, M., Dahmen, I., Müller, C., Di Cerbo, V., Schildhaus, H.U., Altmüller, J., Baessmann, I., Becker, C., de Wilde, B., Vandesompele, J., Böhm, D., Ansén, S., Gabler, F., Wilkening, I., Heynck, S., Heuckmann, J.M., Lu, X., Carter, S.L., Cibulskis, K., Banerji, S., Getz, G., Park, K.S., Rauh, D., Grütter, C., Fischer, M., Pasqualucci, L., Wright, G., Wainer, Z., Russell, P., Petersen, I., Chen, Y., Stoelben, E., Ludwig, C., Schnabel, P., Hoffmann, H., Muley, T., Brockmann, M., Engel-Riedel, W., Muscarella, L.A., Fazio, V.M., Groen, H., Timens, W., Sietsma, H., Thunnissen, E., Smit, E., Heideman, D.A., Snijders, P.J., Cappuzzo, F., Ligorio, C., Damiani, S., Field, J., Solberg, S., Brustugun, O.T., Lund-Iversen, M., Sänger, J., Clement, J.H., Soltermann, A., Moch, H., Weder, W., Solomon, B., Soria, J.C., Validire, P., Besse, B., Brambilla, E., Brambilla, C., Lantuejoul, S., Lorimier, P., Schneider, P.M., Hallek, M., Pao, W., Meyerson, M., Sage, J., Shendure, J., Schneider, R., Büttner, R., Wolf, J., Nürnberg, P., Perner, S., Heukamp, L.C., Brindle, P.K., Haas, S., Thomas, R.K., Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 44:10 (2012), 1104–1110, 10.1038/ng.2396.
11. [11] Rudin, C.M., Durinck, S., Stawiski, E.W., Poirier, J.T., Modrusan, Z., Shames, D.S., Bergbower, E.A., Guan, Y., Shin, J., Guillory, J., Rivers, C.S., Foo, C.K., Bhatt, D., Stinson, J., Gnad, F., Haverty, P.M., Gentleman, R., Chaudhuri, S., Janakiraman, V., Jaiswal, B.S., Parikh, C., Yuan, W., Zhang, Z., Koeppen, H., Wu, T.D., Stern, H.M., Yauch, R.L., Huffman, K.E., Paskulin, D.D., Illei, P.B., Varella-Garcia, M., Gazdar, A.F., de Sauvage, F.J., Bourgon, R., Minna, J.D., Brock, M.V., Seshagiri, S., Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 44:10 (2012), 1111–1116, 10.1038/ng.2405.
12. [12] Sosonkina, N., Hong, S.K., Starenki, D., Park, J.I., Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines. Genes Genomics. 36:6 (2014), 829–841.
13. [13] Collaud, S., Tischler, V., Atanassoff, A., Wiedl, T., Komminoth, P., Oehlschlegel, C., Weder, W., Soltermann, A., Lung neuroendocrine tumors: correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN. BMC Cancer., 15, 2015, 74, 10.1186/s12885-015-1084-5.
14. [14] Morra, F., Luise, C., Visconti, R., Staibano, S., Merolla, F., Ilardi, G., Guggino, G., Paladino, S., Sarnataro, D., Franco, R., Monaco, R., Zitomarino, F., Pacelli, R., Monaco, G., Rocco, G., Cerrato, A., Linardopoulos, S., Muller, M.T., Celetti, A., New therapeutic perspectives in CCDC6 deficient lung cancer cells. Int. J. Cancer 136:9 (2015), 2146–2157, 10.1002/ijc.29263.
15. [15] Merolla, F., Pentimalli, F., Pacelli, R., Vecchio, G., Fusco, A., Grieco, M., Celetti, A., Involvement of H4(D10S170) protein in ATM-dependent response to DNA damage. Oncogene 26:42 (2007), 6167–6175.
16. [16] Leone, V., Mansueto, G., Pierantoni, G.M., Tornincasa, M., Merolla, F., Cerrato, A., Santoro, M., Grieco, M., Scaloni, A., Celetti, A., Fusco, A., CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1. Oncogene 29:30 (2010), 4341–4351, 10.1038/onc.2010.179.
17. [17] Luise, C., Merolla, F., Leone, V., Paladino, S., Sarnataro, D., Fusco, A., Celetti, A., Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity. PLoS One, 7(11), 2012, e49298, 10.1371/journal.pone.0049298.
18. [18] Merolla, F., Luise, C., Muller, M.T., Pacelli, R., Fusco, A., Celetti, A., Loss of CCDC6, the first identified RET partner gene, affects pH2AX S139 levels and accelerates mitotic entry upon DNA damage. PLoS One, 7(5), 2012, e36177, 10.1371/journal.pone.0036177.
19. [19] Morra, F., Luise, C., Merolla, F., Poser, I., Visconti, R., Ilardi, G., Paladino, S., Inuzuka, H., Guggino, G., Monaco, R., Colecchia, D., Monaco, G., Cerrato, A., Chiariello, M., Denning, K., Claudio, P.P., Staibano, S., Celetti, A., FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC. Oncotarget 6:14 (2015), 12697–12709.
20. [20] Pfoh, R., Lacdao, I.K., Saridakis, V., Deubiquitinases and the new therapeutic opportunities offered to cancer. Endocr. Relat. Cancer 22:1 (2015), T35–54, 10.1530/ERC-14-0516.
21. [21] Chauhan, D., Tian, Z., Nicholson, B., Kumar, K.G., Zhou, B., Carrasco, R., McDermott, J.L., Leach, C.A., Fulcinniti, M., Kodrasov, M.P., Weinstock, J., Kingsbury, W.D., Hideshima, T., Shah, P.K., Minvielle, S., Altun, M., Kessler, B.M., Orlowski, R., Richardson, P., Munshi, N., Anderson, K.C., A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22:3 (2012), 345–358, 10.1016/j.ccr.2012.08.007.
22. [22] Fan, Y.H., Cheng, J., Vasudevan, S.A., Dou, J., Zhang, H., Patel, R.H., Ma, I.T., Rojas, Y., Zhao, Y., Yu, Y., Zhang, H., Shohet, J.M., Nuchtern, J.G., Kim, E.S., Yang, J., USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell. Death. Dis., 4, 2013, e867, 10.1038/cddis.2013.400.
23. [23] Colland, F., Formstecher, E., Jacq, X., Reverdy, C., Planquette, C., Conrath, S., Trouplin, V., Bianchi, J., Aushev, V.N., Camonis, J., Calabrese, A., Borg-Capra, C., Sippl, W., Collura, V., Boissy, G., Rain, J.C., Guedat, P., Delansorne, R., Daviet, L., Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol. Cancer Ther. 8:8 (2009), 2286–2295, 10.1158/1535-7163.MCT-09-0097.
24. [24] Chou, T.C., Talaly, P., A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J. Biol. Chem. 252 (1977), 6438–6442.
25. [25] Mascolo, M., Ilardi, G., Merolla, F., Russo, D., Vecchione, M.L., de Rosa, G., Staibano, S., Tissue microarray-based evaluation of Chromatin Assembly Factor-1 (CAF-1)/p60 as tumour prognostic marker. Int. J. Mol. Sci. 13:9 (2012), 11044–11062, 10.3390/ijms130911044 (Epub 2012 Sep 5).
26. [26] Vigliar, E., Malapelle, U., de Luca, C., Bellevicine, C., Troncone, G., Challenges and opportunities of next-generation sequencing: a cytopathologist's perspective. Cytopathology 26:5 (2015), 271–283, 10.1002/cncy.21578.
27. [27] Edelmann, M.J., Nicholson, B., Kessler, B.M., Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases. Expert Rev. Mol. Med., 13, 2011, e35, 10.1017/S1462399411002031.
28. [28] Mamdani, H., Induru, R., Jalal, S.I., Novel therapies in small cell lung cancer. Transl. Lung Cancer Res. 4:5 (2015), 533–544, 10.3978/j.issn.2218-6751.2015.07.20.
29. [29] Owonikoko, T.K., Zhang, G., Deng, X., Rossi, M.R., Switchenko, J.M., Doho, G.H., Chen, Z., Kim, S., Strychor, S., Christner, S.M., Beumer, J., Li, C., Yue, P., Chen, A., Sica, G.L., Ramalingam, S.S., Kowalski, J., Khuri, F.R., Sun, S.Y., Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med. 3:6 (2014), 1579–1594, 10.1002/cam4.317.
30. [30] Vollbrecht, C., Werner, R., Walter, R.F., Christoph, D.C., Heukamp, L.C., Peifer, M., Hirsch, B., Burbat, L., Mairinger, T., Kurt Werner, S., Wohlschlaeger, J., Mairinger, F.D., Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group. Br. J. Cancer 113:12 (2015), 1704–1711, 10.1038/bjc.2015.397.
31. [31] Morselli, E., Tasdemir, E., Maiuri, M.C., Galluzzi, L., Kepp, O., Criollo, A., Vicencio, J.M., Soussi, T., Kroemer, G., Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle. 7:19 (2008), 3056–3061.
32. [32] Karlsson, A., Brunnström, H., Lindquist, K.E., Jirström, K., Jönsson, M., Rosengren, F., Reuterswärd, C., Cirenajwis, H., Borg, Å., Jönsson, P., Planck, M., Jönsson, G., Staaf, J., Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer. Oncotarget 6:26 (2015), 22028–22037.
33. [33] Cardnell, R.J., Feng, Y., Diao, L., Fan, Y.H., Masrorpour, F., Wang, J., Shen, Y., Mills, G.B., Minna, J.D., Heymach, J.V., Byers, L.A., Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin. Cancer Res. 19:22 (2013), 6322–6328, 10.1158/1078-0432.CCR-13-1975.(10.1158).